Last reviewed · How we verify
trastuzumab emtansine [Kadcyla]
trastuzumab emtansine [Kadcyla] is a Small molecule drug developed by Genentech, Inc.. It is currently in Phase 2 development. Also known as: trastuzumab-MCC-DM1, T-DM1, trastuzumab-DM1, Trastuzumab-MCC-DM1.
At a glance
| Generic name | trastuzumab emtansine [Kadcyla] |
|---|---|
| Also known as | trastuzumab-MCC-DM1, T-DM1, trastuzumab-DM1, Trastuzumab-MCC-DM1 |
| Sponsor | Genentech, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- trastuzumab emtansine [Kadcyla] CI brief — competitive landscape report
- trastuzumab emtansine [Kadcyla] updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI
Frequently asked questions about trastuzumab emtansine [Kadcyla]
What is trastuzumab emtansine [Kadcyla]?
trastuzumab emtansine [Kadcyla] is a Small molecule drug developed by Genentech, Inc..
Who makes trastuzumab emtansine [Kadcyla]?
trastuzumab emtansine [Kadcyla] is developed by Genentech, Inc. (see full Genentech, Inc. pipeline at /company/genentech-inc).
Is trastuzumab emtansine [Kadcyla] also known as anything else?
trastuzumab emtansine [Kadcyla] is also known as trastuzumab-MCC-DM1, T-DM1, trastuzumab-DM1, Trastuzumab-MCC-DM1.
What development phase is trastuzumab emtansine [Kadcyla] in?
trastuzumab emtansine [Kadcyla] is in Phase 2.
Related
- Manufacturer: Genentech, Inc. — full pipeline
- Also known as: trastuzumab-MCC-DM1, T-DM1, trastuzumab-DM1, Trastuzumab-MCC-DM1
- Compare: trastuzumab emtansine [Kadcyla] vs similar drugs
- Pricing: trastuzumab emtansine [Kadcyla] cost, discount & access